Kato H, Emura S, Takeuchi N, Enoki M, Oogushi K, Takashima T, Ohmori K, Saito I
Department of Internal Medicine, Saga Medical School, Japan.
J Int Med Res. 1997 Mar-Apr;25(2):108-11. doi: 10.1177/030006059702500208.
A 47-year-old woman with branch retinal arterial occlusion treated with sodium ozagrel is described. The patient presented with acute visual field loss in her right eye. Blood tests demonstrated the elevation of beta-thromboglobulin and platelet factor 4. Sodium ozagrel, a thromboxane A2 synthetase inhibitor, 160 mg daily was administered for 14 days. This treatment prevented exacerbation of retinal arterial thrombosis and produced a marked improvement in the visual field loss. Sodium ozagrel may be a useful drug in the treatment of acute retinal arterial occlusion thought to be caused by thrombosis.
本文描述了一名47岁患有视网膜分支动脉阻塞的女性患者接受奥扎格雷钠治疗的情况。该患者右眼出现急性视野缺损。血液检查显示β-血小板球蛋白和血小板第4因子升高。奥扎格雷钠是一种血栓素A2合成酶抑制剂，每天给予160毫克，持续给药14天。该治疗预防了视网膜动脉血栓形成的加重，并使视野缺损得到显著改善。奥扎格雷钠可能是治疗认为由血栓形成引起的急性视网膜动脉阻塞的一种有效药物。
